Klin Farmakol Farm. 2007;21(2):74-78

Antibiotics in the treatment of severe sepsis - contemporary trends

Roman Kula, Peter Sklienka, Václav Chýlek, Pavel Szturz
ARK FN Ostrava

Severe sepsis is the most common cause of death in ICU. Despite advances in diagnostics and treatment, mortality of severe sepsis remains unacceptably high (28–50 %). Antibiotic therapy and control of the source of infection are the cornerstones of appropriate management of infection and sepsis. Inadequate antibiotic treatment appears to be an important determinant of mortality in patients with severe sepsis and septic shock. Optimalization of the antibiotic treatment includes an early initiation, right antibiotic choice, adequate dosing, and appropriate duration of application.

Keywords: severe sepsis, septic shock, antibiotic therapy, pharmacokinetic, immunomodulation, endotoxin

Published: October 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kula R, Sklienka P, Chýlek V, Szturz P. Antibiotics in the treatment of severe sepsis - contemporary trends. Klin Farmakol Farm. 2007;21(2):74-78.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Angus DC, Wax RS, Epidemiology of sepsis: an update. Crit Care Med 2001; 29: S109-16. Go to original source... Go to PubMed...
    2. Martin GS, Mannino DM, Eaton S et al. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003; 348 (16): 1546-54. Go to original source... Go to PubMed...
    3. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34: 344-353. Go to original source... Go to PubMed...
    4. Černý V, Novák I, Šrámek V. Prevalence těžké sepse v České republice- prospektivní multicentrická jednodenní studie. Anesteziologie a intenzivní medicína 2003; 14 (5): 218-222.
    5. Kollef MH, Sherman G, Ward S et al. Inadequate Antimicrobial Treatment of Sepsis. Chest 1999; 115: 462-474. Go to original source... Go to PubMed...
    6. Kollef MH, Ward S, Sherman G et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000; 28: 3456-3464. Go to original source... Go to PubMed...
    7. Ibrahim EH, Sherman G, Ward S et al. The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patients Outcome in the ICU setting. Chest 2000; 118: 146-155. Go to original source... Go to PubMed...
    8. Lodise TP, McKinnon PS, Swiderski L et al. Outcome Analysis of delayed Antibiotic Treatment for Hospital-Acquired Staphylococcus aureus Bacteriemia. Clin Inf Disease 2003: 36: 1418-23. Go to original source... Go to PubMed...
    9. Garnacho-Montero J, Aldabo-Pallas T, Garnacho-Montero C et al. Timing of adequate antibiotic therapy is a greater determinant of outcome than are TNF and IL-10 polymorphisms in patients with sepsis. Crit Care 2006; 10: R111. Go to original source... Go to PubMed...
    10. Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A et al. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted on ICU with sepsis. Crit Care Med 2003; 31: 2742-2751. Go to original source... Go to PubMed...
    11. Dupont H, Mentec H, Sollet JP et al. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. Intensive Care Med 2001; 27: 355-362. Go to original source... Go to PubMed...
    12. Vidaur L, Rodriguez A, Rello J. Antibiotic Therapy for Sepsis, Severe Sepsis, and Septic Shock: The, ,Tarragona" Strategy. Yearbook of Intensive Care and Emergency Medicine 2004: 229-241.
    13. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. 1995 JAMA 274: 639-644. Go to original source...
    14. Vincent JL. Nosocomial infection in adult intensive-care units. Lancet 2003; 361: 2068-2077. Go to original source... Go to PubMed...
    15. Neuhauser MM, Weinstein RA, Rydman R et al, Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 2003; 289: 885-888. Go to original source... Go to PubMed...
    16. Kollef MH, Fraser VJ. Antibiotic Resistance in the Intensive Care Unit, Ann Intern Med., 2001; 134: 298-314. Go to original source... Go to PubMed...
    17. Gruson D, Hilbert G, Vargas F et al. Rotation an Restricted Use of Antibiotics in a Medical Intensive Care Unit, Am J Resp Crit care Med. 2000; 162: 837-843. Go to original source... Go to PubMed...
    18. Prins JM, Speelman P, Kuijper ER et al. No increase in endotoxin release during antibiotic killing of meningococci. Journal of Antimicrobial Chemotherapy 1997; 39: 13-18. Go to original source... Go to PubMed...
    19. Vincent JL, De Backer D. Microvascular dysfunction as a cause of organ dysfunction in severe sepsis, Critical Care 2005, 9 (Suppl 4): S9-S12. Go to original source... Go to PubMed...
    20. Roberts JA, Lipman J. Antibacterial Dosing in Intensive Care. Clin Pharmacokinet 2006; 45: 755-773. Go to original source... Go to PubMed...
    21. Burchardi H, Schneider H. Economic aspects of severe sepsis" a review of intensive care unit costs, cost of illness and cost effectiveness of therapy. Pharmacoeconomics 2004; 22: 793-813. Go to original source... Go to PubMed...
    22. Schmid A, Pugin J, Chevrolet JC et al. Burden of illness imposed by severe sepsis in Switzerland. Swiss Med Wkly 2004; 134: 97-102. Go to original source... Go to PubMed...
    23. Lepper FM, Held TK, Schneider EM. Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 2002; 28: 824-833. Go to original source... Go to PubMed...
    24. Nau R, Eiffert H. Modulation of Release of Proinflammatory Bacterial Compounds by Antibacterials: Potential Impact on Course of Inflammation and Outcome in Sepsis and Meningitis. Clin Microbiol Rev. 2002; 15: 95-110. Go to original source... Go to PubMed...
    25. Trautmann M, Zick T, Rukavina T et al. Antibiotic-induced release of endotoxin: in-vitro comparison of meropenem and other antibiotics. J Antimicrob Chemother. 1998; 41: 163-169. Go to original source... Go to PubMed...
    26. Trautmann M, Heinemann M, Zict T et al. Antibacterial activity of meropenem against Pseudomonas aeruginosa, including antibiotic-induced morphological changes and endotoxin-liberating effects. Eur J Clin Microbiol Infect Dis. 1998; 17: 754-760. Go to original source... Go to PubMed...
    27. Holzheimer RG. Antibiotic induced endotoxin release and clinical sepsis: a review.J Chemother. 2001; 13 Spec No 1: 159-172. Go to original source... Go to PubMed...
    28. Singer M, Glynne P. Treating critical illness: the importance of first doing no harm.PLoS Med. 2005; 2: e167. Go to original source... Go to PubMed...
    29. Bodi M, Ardanui C, Olona M et al. Therapy of ventilator-associated pneumonia: the Tarragona strategy. Clin Microbiol Infect. 2001; 7: 32-33. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.